Stay updated with breaking news from Chad Messer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...
Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications Thank you, Sarah. Good afternoon, everyone, and welcome to the G1 conference call to discuss our seco...
Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. Benjamin Church -- Head, Corporate Communications & Investor Relations Thank you, operator. Good morning and welcome to Esperion's Second Quarter 2021 Financial Results and Company Update Conference Call. I'm Ben Church and I'm responsible for Investor Relations...
CTIC earnings call for the period ending March 31, 2021.